APG Asset Management N.V. Has $8.16 Million Position in Catalent, Inc. (NYSE:CTLT)

APG Asset Management N.V. lifted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 26.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 155,466 shares of the company’s stock after buying an additional 32,900 shares during the period. APG Asset Management N.V.’s holdings in Catalent were worth $8,157,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its stake in Catalent by 1.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after purchasing an additional 185 shares during the last quarter. Lindbrook Capital LLC raised its stake in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the last quarter. GAMMA Investing LLC lifted its stake in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares during the period. Czech National Bank increased its stake in Catalent by 0.7% in the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Catalent by 1.4% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock valued at $1,082,000 after buying an additional 257 shares in the last quarter.

Catalent Stock Up 0.1 %

Catalent stock opened at $60.33 on Monday. The company has a market capitalization of $10.92 billion, a P/E ratio of -9.89, a P/E/G ratio of 2.32 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average price of $59.69 and a 200-day moving average price of $57.34. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20.

Catalent (NYSE:CTLT) last released its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, equities analysts predict that Catalent, Inc. will post 0.85 EPS for the current year.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,403 shares of company stock valued at $902,503. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Barclays raised their target price on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com initiated coverage on shares of Catalent in a research report on Thursday. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.